Hiperhomocisteinemia na insuficiência renal crônica
Palavras-chave:
homocisteína, hiperhomocisteinemia, insuficiência renal crônicaResumo
A homocisteína é um aminoácido sulfurado proveniente do metabolismo da metionina, cujo acúmulo anormal no plasma é um fator de risco para doenças vasculares, tanto na população em geral como nos pacientes com insuficiência renal crônica. Nestes, a prevalência de indivíduos com hiperhomocisteinemia é bastante elevada, mesmo na fase não dialítica da doença, em que a função renal está diminuída, mas ainda não é necessário tratamento dialítico. O principal fator que parece estar implicado na elevação dos níveis de homocisteína nestes pacientes com insuficiência renal crônica é a perda da massa renal, já que esta exerce uma importante função no metabolismo desse aminoácido. O tratamento da hiperhomocisteinemia na população em geral consiste na suplementação com as vitaminas envolvidas no seu metabolismo (folato, B6 e B12). Porém, em pacientes com insuficiência renal crônica, este tratamento não é completamente eficaz, pois apesar de promover a redução dos níveis de homocisteína, não alcança a normalização dos mesmos na maioria dos pacientes. Este estudo compreende uma revisão da etiologia da hiperhomocisteinemia na insuficiência renal crônica, sua relação com as doenças vasculares, seus principais determinantes e as formas de tratamento.
Referências
Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 1993; 41:S72-7.
Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52(1):10-20.
Dennis V, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int. 1996; 50:S11-7.
Blom HJ, De Vriese S. Why are homocysteine levels increased in kidney failure? A metabolic approach. J Lab Clin Med. 2002; 139(5):262-8.
Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: Current evidence and future prospects. Am J Med. 2002; 112(7):556-65.
Audelin MC, Genest Jr J. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis. 2001; 159(2):497-511.
Arruda VR, Siqueira LH, Gonçalves MS, von Zuben PM, Soares MC, Menezes R, et al. Prevalence of the mutation C677à T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet. 1998; 78(4):332-5.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10(1):111-3.
De Bree A, Verschuren WMM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol. 2001; 154(2):150-4.
Jackes PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr. 2001; 73(3): 613-21.
Mennen LI, de Couray GP, Guilland JC, Ducros V, Bertrais S, Nicolas JP, et al. Homocysteine, cardiovascular disease risk factors, and habitual diet in the French Supplementation with Antioxidant Vitamins and Minerals Study. Am J Clin Nutr. 2002; 76(6):1279-89.
Welch GH, Loscalzo J. Homocysteine and atherothrombosis. N Eng J Med. 1998; 338(15): 1042-50.
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med. 1991; 324(17):1149-55.
Perna AF, Ingrosso D, Satta E, Romano M, Cimmino A, Galletti P, et al. Metabolic consequences of hyperhomocysteinemia in uremia. Am J Kidney Dis. 2001; 38(4 Suppl 1):S85-90.
Moustapha A, Grupta A, Robinson H, Arheart K, Jacobson DW, Schreiber MJ, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999; 55(4):1470-5.
Jungers P, Joly D, Chauveau P, Nguyen AT, Aupetit J, Chadefaux, B. Sustained reduction of hyperhomocysteinemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant. 1999; 14(12):2903-6.
Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol. 1993; 40(4):230-4.
Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000; 57(4): 1727-35.
Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Tranplant. 1997; 12(12):2597-602.
Suliman ME, Stenvinkel P, Heimbürger O, Bàràny P, Lindholm B, Bergström J. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis. 2002; 40(3):480-8.
Malamaci F, Zoccali C, Tripepi G, Ferme I, Benedetto FA, Cataliotti A, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002; 61(2):609-14.
Robinson K, Grupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increase risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996; 94(11): 2743-78.
Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 1999; 55(3):1028-35.
Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Lab Invest. 1996; 56(1):41-6.
Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int. 2001; 60(3):1106-13.
Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron. 2002; 90(1):43-50.
Dierkes J, Domröse U, Bosselmann HP, Neumann KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol. 1999; 51(2):108-15.
Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetcs basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int. 1997; 52(2):495-502.
Van Guldener C, Kulik W, Berger R, Dijkstra DA, Jackobs C, Reyngoud DJ, et al. Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int. 1999; 56(3):1064-71.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Fabiana Baggio NERBASS, Sérgio Antonio DRAIBE, Lilian CUPPARI
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
